EVIO, Inc. (OTCQB: EVIO), a leading provider of cannabis testing and scientific research for the regulated cannabis industry, this morning announced the launch of its EVIO Biosciences Division. Per the update, the new division, which will be led by Dr. Anthony Smith, chief science officer of EVIO, will allow the company to leverage its scientific and human capital expertise to focus on the development of intellectual property and research. The division’s goals encompass emerging health benefits and advanced delivery modes for cannabinoids and cannabis products targeting the human endocannabinoid system. “We are expanding the life sciences part of the company to focus on the need for bioscience applications in cannabis, in addition to analytical testing services,” Smith stated in the news release. “We are focusing on scientific research to support biotechnology and IP development for advanced formulation, manufacturing and delivery processes… The real benefit will be leveraging our R&D in partnership with medical and healthcare providers to bring solutions to real world health problems.”
To view the full press release, visit http://cnw.fm/1nCAH
About EVIO, Inc.
EVIO Inc. is a leading provider of cannabis testing and scientific research for the regulated cannabis industry. The Company’s EVIO Labs division operates coast-to-coast, providing state-mandated ancillary services to ensure the safety and quality of the nation’s cannabis supply. EVIO is on track to have 18 of its state-of-the-art testing facilities by year-end 2018. For more information, visit the company’s website at www.EvioLabs.com
More from CannabisNewsBreaks
About HempWire
HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.
For more information please visit https://www.hempwire.com
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/
HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net
Golden Triangle Ventures (OTC: GTVH) (“GTV”) has completed a major restructuring of its capital structure and…
InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company developing small molecule drug candidates for diseases with…
CannabisNewsWire (CNW), a trusted communications platform within the cannabis sector and a part of InvestorBrandNetwork…
Turning Point Brands (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, recently…
WEED Inc. (OTCQB: BUDZ), a global cannabis and hemp bioresearch company based in the U.S.,…
Flora (NASDAQ: FLGC) has closed a registered direct offering to institutional investors for the aggregate…